Ludovica Taglieri

Ludovica Taglieri

Auto-generated profile, based on publicly available information

Ludovica Taglieri

Department of Experimental Medicine, “Sapienza” University of Rome, Viale Regina Elena 324, I-00161 Rome, Italy

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2015 in Critical Reviews in Oncology/Hematology
Verified
Journal Article
Closed access
FIFrancesca De Iuliis
Francesca De Iuliis
LTLudovica Taglieri
Ludovica Taglieri
GSGerardo Salerno
Gerardo Salerno
RLRosina Lanza
Rosina Lanza
SSSusanna Scarpa
Susanna Scarpa

8 October 2015 in Tumor Biology
Verified
Journal Article
Closed access
PDF file
FIFrancesca De Iuliis
Francesca De Iuliis
GSGerardo Salerno
Gerardo Salerno
LTLudovica Taglieri
Ludovica Taglieri
LBLuciano De Biase
Luciano De Biase
RLRosina Lanza
Rosina Lanza
SSSusanna Scarpa
Susanna Scarpa

1 January 2015 in Tumori Journal
Verified
Journal Article
Closed access
FIFrancesca De Iuliis
Francesca De Iuliis
GSGerardo Salerno
Gerardo Salerno
LTLudovica Taglieri
Ludovica Taglieri
RLRosina Lanza
Rosina Lanza
SSSusanna Scarpa
Susanna Scarpa
Background: Elderly patients with metastatic breast cancer (MBC) have more problems receiving chemotherapy than younger patients, especially with the presence of multiple comorbidities, adverse drug events and functional decline. Low-dose oral administration of cytotoxic agents such as vinorelbine, a semisynthetic vinca alkaloid that interferes with microtubule assembly, leading to arrest of cell division, is usually effective and well tolerated. Methods: From February 2010 to February 2014, 32 patients with MBC, median age 76 years (range 69-83) were treated with oral vinorelbine 30 mg (total dose), one day on and one day off, until disease progression or unacceptable toxicity levels were reported. Toxicity, quality of life and clinical benefit were evaluated. Matched t-tests were conducted to discern whether quality-of-life indicator (p<0.05 was considered significant) differed before and 6 months after treatment. Statistical analysis was performed using Graph Pad Prism 5.0 (GraphPad Software Inc., San Diego, CA, USA). Results: No grade 3 and 4 adverse events were reported. A clinical benefit of 50% was found in our cohort. On and off metronomic vinorelbine oral administration resulted in good tolerability and safe profile in our selected elderly population, and improved patient adherence to therapy. Conclusions: The present study demonstrated that metronomic vinorelbine might be a potential treatment in elderly patients by reducing adverse effects and increasing quality of life, setting the stage for future extensive clinical trials.

2 February 2021 in Molecules
Verified
Journal Article
Open access
PDF file
Valentina Noemi MadiaValentina Noemi Madia
Valentina Noemi Madia
ANAlice Nicolai
Alice Nicolai
Antonella MessoreAntonella Messore
Antonella Messore
ALAlessandro De Leo
Alessandro De Leo
DIDavide Ialongo
Davide Ialongo
Roberta CostiRoberta Costi
Roberta Costi
Background: Anticancer drug resistance is a challenging phenomenon of growing concern which arises from alteration in drug targets. Despite the fast speed of new chemotherapeutic agent design, the increasing prevalence of this phenomenon requires further research and treatment development. Recently, we reported a new aminopyrimidine compound—namely RDS 344—as a potential innovative anticancer agent. Methods: Herein, we report the design, synthesis, and anti-proliferative activity of new aminopyrimidine derivatives structurally related to RDS 3442 obtained by carrying out substitutions at position 6 of the pyrimidine core and/or on the 2-aniline ring of our hit. The ability to inhibit cell proliferation was evaluated on different types of tumors, glioblastoma, triple-negative breast cancer, oral squamous cell carcinomas and colon cancer plus on human dermal fibroblasts chosen as control of normal cells. Results: The most interesting compound was the N-benzyl counterpart of RDS 3442, namely 2a, that induced a significant decrease in cell viability in all the tested tumor cell lines, with EC50s ranging from 4 and 8 μM, 4–13 times more active of hit. Conclusions: These data suggest a potential role for this class of molecules as promising tool for new approaches in treating cancers of different histotype.

22 July 2015 in Cancer Chemotherapy and Pharmacology
Verified
Journal Article
Closed access
PDF file
FIFrancesca De Iuliis
Francesca De Iuliis
GSGerardo Salerno
Gerardo Salerno
LTLudovica Taglieri
Ludovica Taglieri
SSSusanna Scarpa
Susanna Scarpa

19 March 2016 in Investigational New Drugs
Verified
Journal Article
Closed access
PDF file
FIFrancesca De Iuliis
Francesca De Iuliis
LTLudovica Taglieri
Ludovica Taglieri
GSGerardo Salerno
Gerardo Salerno
AGAnna Giuffrida
Anna Giuffrida
BMBernardina Milana
Bernardina Milana
SSSusanna Scarpa
Susanna Scarpa